{"filings":[{"id":1001476,"accession_number":"0001140361-26-024949","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2026-06-11T20:44:20+00:00","items":["1.01","1.02","2.01","3.01","5.01","2.03","3.03","5.03","5.02","7.01","9.01"],"status":"ready","headline":"Chiesi completes $27/share acquisition of KalVista; shares cease trading on Nasdaq","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer accepted 43,152,532 shares (~77.8% of outstanding) at $27.00 cash per share.","Back-end merger closed June 11, 2026; KalVista now wholly owned by Chiesi Group.","KalVista stock halted June 10 and delisted from Nasdaq Global Market effective June 11.","Chiesi takes ownership of EKTERLY (sebetralstat), oral on-demand HAE treatment approved in US, EU, Japan.","Transaction bonuses aggregate $10.5M for CEO, CMO, CFO; gross-up agreement with CFO for Section 4999 excise tax."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92365,"accession_number":"0001140361-26-017656","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Chiesi Group to acquire KalVista Pharmaceuticals for $27.00 per share, ~$1.9bn","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Chiesi will acquire all KalVista shares for $27.00/sh cash, a 36% premium to 30-day VWAP as of April 28, 2026.","Total equity consideration approximately $1.9bn; transaction expected to close in Q3 2026 subject to regulatory approvals and majority tender.","KalVista's key asset is EKTERLY (sebetralstat), first oral on-demand HAE therapy; US launch in July 2025 generated $49M in 2025 sales.","Termination fee of $66.4M payable by KalVista if it accepts a superior offer; transaction not subject to financing condition.","Both companies' boards unanimously approved the merger; KalVista board recommends stockholders tender shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103175,"accession_number":"0001193125-26-122784","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista reports $49.1M EKTERLY revenue in 8mo transition period, 1,702 patient start forms","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Global net product revenue of $49.1M from EKTERLY (sebetralstat) for May–Dec 2025; first commercial sales since launch on July 7, 2025.","1,702 patient start forms received in US through Feb 2026, nearly 20% of HAE population; 724 unique prescribers activated.","R&D expenses $33.4M (down from $52.2M YoY); SG&A $124.7M (up from $64.9M) due to commercialization costs.","Cash, equivalents and marketable securities $300.2M as of Dec 31, 2025; company expects to fund through profitability.","Pediatric Phase 3 KONFIDENT-KID trial fully enrolled; interim data to be presented at 2026 Global Angioedema Summit; NDA filing planned Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103174,"accession_number":"0001193125-26-007801","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"KalVista reports preliminary Q4 EKTERLY revenue of ~$35M, full-year ~$49M; 1,318 patient start forms","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited global net product revenue: ~$35M for Q4 2025, ~$49M for full year 2025.","1,318 patient start forms and 580 unique prescribers activated in the US through Dec 31, 2025.","Prescription refills surpassed initial prescriptions as the primary revenue driver in Q4.","Entered Latin America partnership with Multicare Pharma for Brazil, Argentina, Colombia, Mexico.","Expect to file NDA for pediatric HAE patients (ages 2-11) in Q3 2026; US launch anticipated in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":49078000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119410,"accession_number":"0001193125-25-274405","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista reports $13.7M Q3 net product revenue from EKTERLY launch; 937 patient start forms through Oct","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $13.7M for Q3 ended Sept 30, 2025, first full quarter of EKTERLY commercial launch.","937 patient start forms received and 423 unique prescribers activated through Oct 31, 2025.","Cash and marketable securities of $309.2M; expects to fund through profitability.","EKTERLY approved in EU, Switzerland, and Australia; Germany launch initiated Oct 2025.","R&D expenses $12.0M (down from $18.7M); SG&A $46.5M (up from $24.8M) due to commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":13700000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119409,"accession_number":"0001193125-25-230906","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"KalVista appoints Bilal Arif as COO and Linea Aspesi as Chief People Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bilal Arif appointed COO effective Oct 6, 2025; base salary $520k, annual bonus target 40%, option grant of 100,000 shares.","Linea Aspesi appointed Chief People Officer; also receives inducement option grant of 100,000 shares.","Both options vest over 4 years: 1/4th on 1-year anniversary, then monthly vesting.","Appointments support global launch of EKTERLY for hereditary angioedema.","Arif was EVP at Sarepta Therapeutics; Aspesi was Chief Admin Officer at Editas Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119408,"accession_number":"0001193125-25-227478","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"KalVista appoints Bethany Sensenig to Board and Audit Committee; annual meeting results filed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bethany Sensenig appointed to Board and Audit Committee effective October 1, 2025.","Sensenig is CFO and Head of Operations at Radius Health; former Biogen VP of Finance.","Nancy Stuart moves off Audit Committee but remains on Board and joins Compensation Committee.","Stockholders re-elected Benjamin Palleiko and Brian Pereira as Class I directors for three-year terms.","Advisory vote on named executive officer compensation passed with 33.6M shares for vs 4.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135967,"accession_number":"0001193125-25-223262","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","8.01","2.03","3.02","9.01"],"status":"ready","headline":"KalVista closes $143.75M convertible notes offering; net proceeds ~$139M for EKTERLY","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $143.75M in 3.250% Convertible Senior Notes due 2031, including full exercise of $18.75M greenshoe.","Net proceeds ~$139M after discounts and expenses; used for working capital and EKTERLY commercialization.","Initial conversion rate 59.4919 shares/$1,000 (conversion price ~$16.81), 30% premium over $12.93 close.","Notes are senior, unsecured, callable after Oct 5, 2028 if stock price meets 130% conversion price threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135966,"accession_number":"0001193125-25-200742","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista Q1: EKTERLY approved in US/UK; 460 patient start forms; positive CHMP opinion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EKTERLY (sebetralstat) FDA approved July 7, 2025; UK MHRA authorized same month; positive CHMP opinion; EU decision expected Oct 2025.","Received 460 patient start forms through August 29, 2025 (nearly 5% of US HAE patients).","Net product revenue $1.4M from US sales; R&D expenses $15.2M (down 43% YoY); SG&A $44.7M (up 154% YoY due to commercialization).","Cash and marketable securities $191.5M as of July 31, 2025; runway into 2027.","Orphan designation maintained in EU; 10 years market exclusivity; one of only two HAE medicines with orphan status."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":1400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135965,"accession_number":"0001193125-25-185382","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"KalVista sets June 18, 2026 as annual meeting date; stockholder deadlines revised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2026 Annual Meeting set for June 18, 2026; changed >30 days from 2025 meeting.","Stockholder proposals for proxy inclusion due January 6, 2026.","Other proposals or director nominations due August 31, 2025 (10 days after this 8-K).","Universal proxy rule compliance required for soliciting proxies in support of non-company nominees.","Advance notice procedures per Bylaws apply; notice to Cambridge, MA address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135964,"accession_number":"0001193125-25-157382","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista FY2025: FDA approved EKTERLY; cash $220.6M; R&D down, G&A up","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved EKTERLY (sebetralstat) on July 7, 2025 as first oral on-demand HAE treatment; U.S. launch underway.","Cash and marketable securities $220.6M at April 30, 2025, providing runway into 2027.","R&D expenses $71.7M (down from $86.2M); G&A expenses $116.3M (up from $54.3M) driven by pre-commercial costs.","Entered licensing agreements for sebetralstat in Japan (Kaken, $11M upfront) and Canada (Pendopharm).","Six global regulatory submissions under review; new clinical data presented at EAACI, C1-INH, and EAC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135963,"accession_number":"0001193125-25-155885","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"KalVista receives FDA approval for EKTERLY (sebetralstat), first oral on-demand HAE treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved EKTERLY for acute attacks of hereditary angioedema in patients 12+ years; first oral on-demand therapy.","Phase 3 KONFIDENT trial (136 patients, 20 countries) showed faster symptom relief vs placebo; published in NEJM.","KONFIDENT-S open-label extension: median 10 minutes to treat attacks after onset; 1.3 hours to symptom relief for laryngeal/abdominal/breakthrough attacks.","Launching immediately; prescriptions available today; KalVista Cares patient support program launched.","CEO Ben Palleiko says EKTERLY has potential to become foundational HAE treatment; conference call at 8:30am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152995,"accession_number":"0001193125-25-117878","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"KalVista COO Jebediah T. Ledell resigns effective May 12, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Jebediah T. Ledell resigned effective immediately on May 12, 2025.","No replacement or interim COO has been named by the company.","Resignation filed under Item 5.02; no reason for departure provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152994,"accession_number":"0001193125-25-075100","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"KalVista licenses sebetralstat Japan rights to Kaken; $11M upfront, up to $24M total plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $11M plus up to $11M regulatory milestone expected in early 2026.","Also eligible for commercial milestones and mid-twenties% royalties on Japan NHI price.","Sebetralstat is an investigational oral on-demand HAE treatment; could be first oral in Japan.","Kaken will leverage regional expertise; KalVista aims for global commercial launches starting 2025.","Orphan Drug Designation received from MHLW; NDA submitted in Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171780,"accession_number":"0001193125-25-055602","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"KalVista changes fiscal year-end from April 30 to December 31","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved change effective March 13, 2025; new fiscal year begins January 1, 2026.","Transition report on Form 10-KT will cover eight-month period May 1 through Dec 31, 2025.","During transition, a 10-Q for quarter ending July 31, 2025 will be filed, then quarters shift to Sept 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171779,"accession_number":"0000950170-25-038015","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista Q3 fiscal 2025: $253.2M cash, sebetralstat regulatory progress; PDUFA June 17","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No revenue; R&D expense $12.6M (down from $22.5M YoY); G&A $30.3M (up from $10.6M) due to pre-commercial activities.","Cash, cash equivalents and marketable securities of $253.2M as of Jan 31, 2025.","Sebetralstat NDA submitted in Japan, orphan drug designation granted; U.S. PDUFA date June 17, 2025.","Raised $160M gross proceeds in Nov 2024 via synthetic royalty financing and equity offerings to fund launch.","Field sales team onboarded; Jeb Ledell appointed COO; new data presented on laryngeal attacks, adolescents, and LTP patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188782,"accession_number":"0001193125-24-279016","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"KalVista appoints Jeb Ledell as COO; base salary $500k, 100k stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jebediah T. Ledell appointed COO effective December 16, 2024; brings 20+ years biotech ops experience.","Compensation: $500k base salary, 40% bonus target, inducement options for 100,000 shares vesting over 4 years.","Ledell previously COO at AVEO Oncology, Enzyvant Therapeutics, Compass Therapeutics, and Horizon Discovery Group.","Appointment supports KalVista's preparation for potential sebetralstat launch (HAE); PDUFA goal date June 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188781,"accession_number":"0000950170-24-133693","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista Q2 FY2025: No revenue, cash $135.8M; sebetralstat NDA accepted with PDUFA June 17, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $16.6M, G&A $29.2M; pro forma cash $292.2M after $156.4M net November raise.","FDA accepted NDA for oral on-demand HAE treatment sebetralstat; PDUFA date June 17, 2025.","MAA submissions in UK, Switzerland, Australia, Singapore via Access Consortium; EMA MAA validated in August.","Appointed Brian Piekos as CFO; raised $160M total via synthetic royalty financing and equity offerings.","New data presented at ACAAI and HAEi Global Angioedema Forum supporting early attack treatment and anxiety reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":50000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188780,"accession_number":"0001193125-24-265612","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"KalVista appoints Laurence Reid, Ph.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laurence Reid appointed to KalVista Board effective Nov 23, 2024; term expires at 2027 annual meeting.","Compensation: initial option for 17,000 shares, $42,500 annual cash retainer, annual option for 10,000 shares.","Reid brings over 30 years biotech experience; was CEO of Decibel Therapeutics prior to Regeneron acquisition.","Reid's appointment comes as KalVista progresses sebetralstat toward FDA PDUFA date of June 17, 2025.","Board determined Reid independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188779,"accession_number":"0001193125-24-250665","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"KalVista raises $60M in public offering and private placement to fund sebetralstat","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 5.5M shares at $10.00 per share for gross proceeds of $55M; net ~$51.3M.","Concurrent private placement of 500K shares to DRI Healthcare Acquisitions LP for $5M gross; net ~$4.7M.","Proceeds will fund continued clinical development of sebetralstat and pre-commercialization activities.","Offering and private placement expected to close November 5, 2024; closings not contingent on each other.","Jefferies, BofA Securities, TD Cowen, and Stifel serving as joint book-running managers and placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188778,"accession_number":"0001193125-24-250223","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"KalVista secures up to $179M synthetic royalty financing with DRI for sebetralstat launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $100M; potential total up to $179M including $22M optional approval payment and $57M sales milestone.","Tiered royalties: 5% on net sales up to $500M, 1.1% on $500M-$750M, 0.25% above $750M; rate increases if optional payment taken.","Additional $22M optional if US approval by Sep 30, 2025; PDUFA date June 17, 2025 for sebetralstat (oral HAE therapy).","DRI expressed non-binding interest in up to $5M private placement of KalVista common stock.","Royalty financing non-dilutive; proceeds to fund commercial launch of sebetralstat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188777,"accession_number":"0000950170-24-112904","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"KalVista shareholders elect directors, ratify auditor, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["William Fairey and Nancy Stuart elected as Class III directors with 30.2M and 19.3M votes 'For', respectively; Stuart faced 11.7M votes 'Against'.","Deloitte & Touche ratified as independent auditor for FY ending April 30, 2025 with 39.3M votes 'For'.","Advisory say-on-pay proposal approved with 26.6M 'For', 4.5M 'Against'.","Broker non-votes of 8.3M shares recorded for director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205249,"accession_number":"0000950170-24-105182","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"KalVista appoints Brian Piekos as CFO effective Sept 9; 100K stock option inducement granted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Piekos joins as CFO; previously CFO of Elicio Therapeutics and Gemini Therapeutics.","Piekos receives $460K base salary, 40% bonus target, and 100K stock options at $11.87 with 4-year vest.","Employment agreements for CEO Ben Palleiko and CMO Paul Audhya amended (severance, Section 280G updates).","KalVista highlights Piekos' experience as it prepares for sebetralstat commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205248,"accession_number":"0000950170-24-104032","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista Q1 net loss $40.4M; FDA accepts NDA for sebetralstat, PDUFA June 17, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.4M ($0.87/share) vs $25.3M prior year; no revenue recognized.","Cash and securities $174.3M at July 31, down from $210.4M on April 30.","FDA accepted NDA for oral sebetralstat for HAE; PDUFA goal date June 17, 2025.","EMA validated MAA submission for sebetralstat; UK/Japan filings planned later in 2024.","Phase 3 KONFIDENT-KID pediatric trial initiated dosing with oral disintegrating tablet."],"consensus_eps_estimate":-0.8915,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205247,"accession_number":"0000950170-24-085653","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"KalVista Pharmaceuticals enters lease for HQ and lab in Framingham; aggregate rent ~$11.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 32,110 sq ft at 200 Crossing Blvd, Framingham, MA, as corporate HQ and lab space.","Commencement on or about April 30, 2025; lease expires December 31, 2034.","Aggregate base rent payments of approximately $11.2 million over the term.","Security deposit of ~$652,800 in the form of a letter of credit.","Company to pay pro rata share of operating expenses and certain taxes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205246,"accession_number":"0000950170-24-082997","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista submits NDA for sebetralstat; FY2024 net loss $126.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NDA submitted to FDA for sebetralstat, first oral on-demand HAE treatment; potential approval H1 2025.","FY2024 net loss $126.6M ($3.44/share) vs $92.9M ($3.33) prior year; no revenue.","Cash, cash equivalents and marketable securities $210.4M, up from $149.4M; raised $150.1M net in Feb 2024 offering.","R&D expenses $86.2M (prior $80.3M); G&A $54.3M (prior $30.6M) driven by commercial planning and employee costs.","Promoted Benjamin Palleiko to CEO in March 2024; strategic review of preclinical Factor XIIa program ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222131,"accession_number":"0000950170-24-046481","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"KalVista appoints William Fairey to Board; commercial expertise in rare disease","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Fairey appointed to Board effective April 18, 2024 as Class III director.","Mr. Fairey previously served as Chief Commercial Officer at MyoKardia and COO at ChemoCentryx.","Initial compensation includes options to purchase 17,000 shares and $42,500 annual cash retainer.","Appointment adds commercial launch experience ahead of planned FDA submission for sebetralstat.","Mr. Fairey is independent under Nasdaq and SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241652,"accession_number":"0000950170-24-029342","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista reports Phase 3 KONFIDENT success for sebetralstat, CEO transition, $150M financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 KONFIDENT met all primary and key secondary endpoints; sebetralstat safety profile similar to placebo.","CEO transition: Benjamin Palleiko appointed CEO, succeeding prior CEO as part of commercial preparation.","Closed underwritten offering netting ~$150.1M from 7.0M shares and 3.5M pre-funded warrants at $15.25/share.","Net loss $29.0M ($0.84/sh) for fiscal Q3 ended Jan 31, 2024, vs $21.3M ($0.75) YoY; cash $75.6M.","NDA submission on track for H1 2024; UK MHRA granted Innovation Passport for sebetralstat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241651,"accession_number":"0001193125-24-061344","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"KalVista appoints Benjamin Palleiko as CEO; Crockett resigns in planned transition","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["T. Andrew Crockett resigned as CEO and board director effective March 6, 2024, not due to any disagreement.","Benjamin L. Palleiko appointed CEO and to the Board; he was President/CBO/CFO and remains principal financial officer.","Palleiko receives base salary of $661,800/year, 60% bonus target, and 250,000 RSUs vesting quarterly over 4 years.","Crockett separation includes 18 months base salary lump sum, full FY2024 target bonus, and 150,000 RSU/PSU acceleration.","Sebetralstat NDA filing on track for H1 2024 in US; Europe and Japan filings in H2 2024 after positive Phase 3 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241650,"accession_number":"0001193125-24-038522","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"KalVista prices $160.1M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 7,016,312 shares at $15.25 and pre-funded warrants for 3,483,688 shares; gross proceeds $160.1M.","Net proceeds estimated at ~$150.1M to fund sebetralstat development and oral Factor XIIa program.","Cash, cash equivalents and marketable securities approximately $76M as of Jan 31, 2024 (preliminary).","Underwriters granted 30-day option to purchase up to 1,575,000 additional shares at same price.","Closing expected Feb 20, 2024; Jefferies, Leerink, Stifel, Cantor joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241649,"accession_number":"0001193125-24-036224","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"KalVista terminates $100M ATM sales agreement with Cantor Fitzgerald; no shares sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Controlled Equity Offering Sales Agreement with Cantor, effective Feb 14, 2024.","Agreement allowed up to $100M in common stock sales; company sold zero shares under it.","Cantor waived notice period, making termination immediate upon close of business Feb 14.","Termination has no effect on operations or capital; company retains other financing avenues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241648,"accession_number":"0001193125-24-032859","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"KalVista announces positive Phase 3 KONFIDENT results; sebetralstat meets all endpoints with rapid symptom relief","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sebetralstat 300 mg achieved beginning of symptom relief in median 1.61 hours vs placebo 6.72 hours (p<0.0001).","Trial met all primary and key secondary endpoints; no treatment-related SAEs and no withdrawals due to AEs.","Treatment-related adverse event rates: 2.3% for 300 mg, 2.2% for 600 mg, 4.8% for placebo.","Plan to submit NDA to U.S. FDA in first half of 2024 and in EU and Japan later in 2024.","Largest HAE trial ever with 136 patients from 66 sites across 20 countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259098,"accession_number":"0000950170-23-068816","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista hits Phase 3 attack target for sebetralstat; NDA on track for H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 KONFIDENT trial achieved targeted number of attacks; data readout early 2024, NDA filing expected H1 2024.","Received Orphan Drug Status from Switzerland for sebetralstat, providing 15-year market protection.","Net loss of $27.7M ($0.80/share) for Q2 FY24 vs. $22.3M ($0.90/share) year ago; revenue nil.","Cash, equivalents and marketable securities $103.2M at Oct 31, 2023, down from $149.4M at Apr 30, 2023.","R&D expenses $19.1M; G&A expenses $10.7M, both up YoY due to trial costs and commercial build-out."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276367,"accession_number":"0000950170-23-050440","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"KalVista stockholders approve officer exculpation amendment, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved certificate of amendment to limit officer liability under Delaware law (20.2M for, 2.5M against).","Elected Patrick Treanor and Edward W. Unkart as Class II directors for three-year terms.","Ratified Deloitte & Touche as independent auditor for FY ending April 30, 2024 (30.8M for, 1.6K against).","Non-binding advisory vote on named executive officer compensation passed (20.0M for, 2.7M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276366,"accession_number":"0000950170-23-047036","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista reports Q1 FY2024 net loss $25.3M; KONFIDENT phase 3 enrollment achieved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.3M ($0.74/share) vs $23.0M ($0.94/share) in prior-year quarter.","Cash, equivalents and marketable securities $123.3M vs $149.4M as of April 30, 2023.","Phase 3 KONFIDENT trial for sebetralstat hit enrollment target of 114 patients; data readout on track for Q4 2023.","NDA submission planned for H1 2024; Nicole Sweeny appointed Chief Commercial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276365,"accession_number":"0000950170-23-032300","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista FY2023 net loss $92.9M; sebetralstat Phase 3 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 KONFIDENT trial achieved target enrollment (114 patients); data readout expected Q4 2023; NDA planned H1 2024.","Net loss FY2023 $92.9M ($3.33/share) vs $82.3M ($3.36/share); no revenue.","R&D expenses $80.3M (FY2023) vs $70.2M; G&A $30.6M vs $26.4M.","Cash, equivalents and marketable securities $149.4M; funded into 2025 after $58M registered direct offering.","Promoted Benjamin Palleiko to President; appointed Brian Pereira as Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294072,"accession_number":"0000950170-23-027974","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"KalVista amends CFO employment agreement raising base salary to $565K; updates bylaws for universal proxy rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Benjamin L. Palleiko's base salary raised to $565,000 (effective May 1, 2023); target bonus increased to 50% of salary.","Severance: 15 months base salary and COBRA if terminated without cause/for good reason before Change in Control.","If terminated within 2 years after Change in Control: 21 months base salary, full target bonus, full equity vesting, COBRA.","Bylaws amended for DGCL updates, universal proxy rules, and exclusive forum (Delaware Chancery Court)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314696,"accession_number":"0000950170-23-007054","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista reports Q3 net loss $21.3M; sebetralstat phase 3 enrollment >50%, data H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.3M ($0.75 per share), no revenue; R&D $20.1M, G&A $6.9M.","Phase 3 KONFIDENT trial enrollment exceeds 50%; topline data expected H2 2023.","FDA guidance: no efficacy trials required for ODT sNDA; PMDA guidance for Japan.","Cash and securities $171.7M; $58M financing extends runway into 2025.","Phase 2 sebetralstat data published in The Lancet; CFO Palleiko promoted to President."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314695,"accession_number":"0000950170-23-000230","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"KalVista promotes CFO/CBO Palleiko to President; cites $190M cash for sebetralstat launch prep","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Benjamin L. Palleiko appointed President effective Jan 4, 2023, while retaining CFO and CBO roles.","Promotion follows $58M registered direct offering in Dec 2022 at 17% premium; pro forma cash ~$190M.","Palleiko to lead commercial organization for planned launch of sebetralstat, an oral HAE therapy in Phase 3.","KalVista expects KONFIDENT Phase 3 data in H2 2023 and NDA filing in H1 2024; cash runway into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333099,"accession_number":"0001193125-22-312030","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2022-12-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"KalVista raises ~$58M in registered direct offering of 9.48M shares at $6.00/share plus warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9,484,199 shares at $6.00 per share, plus pre-funded warrants for 182,470 shares at $5.999 each.","Net proceeds expected ~$58M for clinical trials, commercial development, R&D, and working capital.","Offering closes Dec 28, 2022; post-closing shares outstanding ~34.1M (dilution of ~9.7M shares).","No underwriter; securities offered under existing shelf registration (File No. 333-256378)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333098,"accession_number":"0000950170-22-026236","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista terminates KVD824 Phase 2 trial over liver enzyme elevations; net loss widens to $22.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 KOMPLETE trial for KVD824 terminated due to patient liver enzyme elevations; future development uncertain.","Net loss of $22.3M ($0.90 per share) for quarter ended Oct 31, 2022 vs $19.7M ($0.80) a year ago.","Cash, cash equivalents and marketable securities at $122.3M as of Oct 31, 2022, down from $166.2M at Apr 30.","Phase 3 KONFIDENT trial for sebetralstat on track; data expected H2 2023, NDA filing planned H1 2024.","Appointed Brian J. G. Pereira, M.D., as Chairman of the Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333097,"accession_number":"0000950170-22-019610","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"KalVista Pharmaceuticals appoints Brian J.G. Pereira as Chairman; Martin Edwards resigns in planned transition","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin Edwards resigned as Chairman and director effective immediately; departure not due to any disagreement.","Brian J.G. Pereira appointed Chairman; previously a board member since 2019 and President & CEO of Visterra.","Annual meeting results: T. Andrew Crockett and Brian J.G. Pereira elected as Class I directors.","Deloitte & Touche ratified as auditor for FY ending April 30, 2023; advisory say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350554,"accession_number":"0000950170-22-018243","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista Q1 net loss $23.0M ($0.94/share); cash $142.1M, down $24.1M from April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue; R&D spending rose to $18.2M (vs. $13.7M a year ago), driven by Phase 3 KONFIDENT and preclinical costs.","Net loss widened to $23.0M from $16.1M; cash burn reflects higher operating expenses.","KVD824 Phase 2 KOMPLETE trial passed 50% enrollment; top-line data expected mid-2023.","Open-label extension (KONFIDENT-S) initiated for sebetralstat; Phase 3 KONFIDENT data expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350553,"accession_number":"0000950170-22-012523","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2022-07-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista FY2022 net loss $82.3M (-$3.36/share); cash $166.2M; sebetralstat Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $82.3M ($3.36 loss per share) vs $46.2M ($2.42) prior year; R&D spend $70.2M.","Cash & marketable securities $166.2M at April 30, 2022, down from $248.9M; funding into early 2024.","Sebetralstat Phase 3 KONFIDENT trial enrollment on track; data expected H2 2023. EU orphan designation received.","KVD824 Phase 2 KOMPLETE trial for HAE prevention on track; data expected mid-2023.","Appointed Patrick A. Treanor (COO of Pathalys Pharma) to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367726,"accession_number":"0000950170-22-010855","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"KalVista director Daniel Soland resigns; Patrick Treanor appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Soland resigned from board and committees effective May 25, 2022; not due to any disagreement with the Company.","Patrick Treanor appointed as Class II director effective May 26, 2022, term expiring at 2024 annual meeting.","Treanor to receive initial option for 17,000 shares, $42,500 annual cash retainer, and annual option for 10,000 shares after one year.","Treanor determined independent under NASDAQ rules; will execute standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387077,"accession_number":"0000950170-22-003382","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista reports Q3 net loss $22.5M; KVD900 Phase 3 trial initiated, data expected H2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $22.5M ($0.92/share) vs $10.0M loss ($0.56) YoY; R&D spend $19.7M (up from $9.1M).","Cash and securities $194.8M at Jan 31, 2022, down from $248.9M at Apr 30, 2021.","Initiated Phase 3 KONFIDENT trial for KVD900 on-demand HAE treatment; data expected H2 2023.","Phase 2 KOMPLETE trial for KVD824 (prophylaxis) enrolling on track; data expected mid-2023.","Factor XIIa inhibitor program advancing; first IND anticipated in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387076,"accession_number":"0000950170-22-002956","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"KalVista initiates Phase 3 KONFIDENT trial of KVD900 for HAE attacks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KVD900 is first potential oral on-demand therapy for HAE; all current on-demand therapies are injectable.","Trial is double-blind, placebo-controlled, crossover; two doses (300 mg, 600 mg) vs placebo.","Primary endpoint: time to beginning of symptom relief per Patient Global Impression of Change (PGI-C) scale.","Enrollment: minimum 84 adolescent and adult patients at ~60 sites in 20 countries.","Top-line data expected in second half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404999,"accession_number":"0000950170-21-005122","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KalVista reports Q2 net loss $19.7M; advances HAE oral candidates KVD900 and KVD824","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.7M ($0.80 per share) for quarter ended Oct 31, 2021 vs $10.4M ($0.58) year ago.","Cash, equivalents and marketable securities $209.8M as of Oct 31, 2021; funded into early 2024.","Preparing to initiate Phase 3 trial for KVD900 (on-demand HAE) in Q1 2022; FDA confirmed trial design.","Phase 2 KOMPLETE trial for KVD824 (prophylactic HAE) enrolling patients; regulatory approvals in 12 of 13 countries.","R&D expenses increased to $17.5M from $9.1M due to preclinical, Phase 2 and Phase 3 preparation costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404998,"accession_number":"0001564590-21-049879","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2021-10-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"KalVista stockholders elect three Class III directors at 2021 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Albert Cha, Martin Edwards, and Nancy Stuart as Class III directors for three-year terms expiring 2024.","Ratified Deloitte & Touche as independent auditor for fiscal year ending April 30, 2022: 22.6M for, 13.6K against.","Approved non-binding advisory vote on named executive officer compensation: 19.7M for, 2.5M against.","All proposals passed; broker non-votes were 464,900 on director elections and compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424037,"accession_number":"0001564590-21-047970","cik":1348911,"company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","form_type":"8-K","filed_at":"2021-09-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA lifts clinical hold on KalVista's Phase 2 KVD824 trial for HAE prophylaxis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA removed clinical hold on Phase 2 KOMPLETE trial of KVD824 for oral prophylactic treatment of hereditary angioedema.","Clinical hold lifted after FDA review of KalVista's responses on certain preclinical studies of KVD824.","Protocol refinements made; company working to resume study activities as soon as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1426323403.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-15T23:59:59+00:00|424037"}